Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.
Abstract
2011 Outstanding Scientific Achievement Award.The award was presented at the Association's 71st Scientific Sessions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [141]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmsr043743 · Cited by 2,612 · cited 1×
“Type 2 diabetes and obesity, often referred to as “diabesity,” constitute two closely linked health threats of modern societies that continue to rise in prevalence despite decades of research investment (1).”
BackgroundCirculating Ghrelin Levels Are Decreased in Human Obesity
Tschöp, M., Weyer, C., Tataranni, P. A., Devanarayan, V., Ravussin, E., & Heiman, M. L. (2001) · Diabetes · doi:10.2337/diabetes.50.4.707 · Cited by 2,008 · cited 2×
“afferent information as it typically responds most efficiently to distinct patterns rather than to changes in a single peripheral signal, for example, altered circulating concentrations of the adiposity promoting stomach hormone ghrelin (13).”
BackgroundSelf-citationThe Path to Personalized Medicine
Hamburg, M. A., & Collins, F. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006304 · Cited by 1,970
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000167407.83915.e7 · Cited by 1,944
The role of neuropeptide Y in the antiobesity action of the obese gene product
Stephens, T. W., Basinski, M., Bristow, P. K., Bue-Valleskey, J. M., Burgett, S. G., Craft, L., Hale, J., Hoffmann, J., Hsiung, H. M., Kriauciunas, A., et al. (1995) · Nature · doi:10.1038/377530a0 · Cited by 1,498
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641 · cited 3×
“Numerous coagonists with differing ratios of glucagon versus GLP-1 agonism were designed and synthesized followed by extensive testing by in vitro and in vivo methods (19) (Fig.”
BackgroundMethodSelf-citationRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436 · cited 2×
“They demonstrated in rodents and humans that combined treatment with parallel injections of the pancreatic hormone amylin and leptin synergistically enhanced body weight loss and metabolism to an extent not possible with monotherapy (15).”
BackgroundBariatric Surgery for Morbid Obesity
DeMaria, E. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmct067019 · Cited by 427
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Ex-9 and most GIPR antagonists are in fact nonselective and function as partial agonists at their respective receptors (Tschöp and DiMarchi, 2012).”
BackgroundIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
“Future therapeutic strategies targeting a combination of these hormones are advancing into clinical studies, which could result in a superior appetitesuppressing hormone profile and greater weight loss than single-agent therapies have provided so far [163,164].”
BackgroundGLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
“To further support a role for GLP-1R signaling in regulating food reward, recent fMRI studies in obese and obese T2DM patients have demonstrated that intravenous infusion of exenatide decreases the activation of brain regions involved in mediating food reward (van Bloemendaal et al., 2014).”
BackgroundResultJall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107
“Whereas most previous weight-loss pharmacotherapies are hampered by limited efficacy or unacceptable adverse effects, there is hope resting on recent advances in the development of single molecules which promote their biological action through simultaneous agonism at multiple key metabolic receptors [17,18].”
BackgroundSelf-citationRavn, P., Madhurantakam, C., Kunze, S., Matthews, E., Priest, C., O'Brien, S., Collinson, A., Papworth, M., Fritsch-Fredin, M., Jermutus, L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426288 · Cited by 86
He, Y., Haynes, W., Meyers, C. D., Amer, A., Zhang, Y., Mahling, P., Mendonza, A. E., Ma, S., Chutkow, W., & Bachman, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13654 · Cited by 81
Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Boylan, M. O., Glazebrook, P. A., Tatalovic, M., & Wolfe, M. M. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00345.2015 · Cited by 65
“It also corrected obesityrelated insulin resistance and pancreatic insulin deficiency, two of the etiologic mechanisms responsible for “diabesity” (6, 38).”
BackgroundResultA link between hepatic glucose production and peripheral energy metabolism via hepatokines
Abdul-Wahed, A., Gautier-Stein, A., Casteras, S., Soty, M., Roussel, D., Romestaing, C., Guillou, H., Tourette, J.-A., Pleche, N., Zitoun, C., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.05.005 · Cited by 62
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M. A., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 56
“In addition, the earlier accepted translation of results from GIPR knock-out mice has been questioned [60,61].”
BackgroundResultPathak, V., Gault, V. A., Flatt, P. R., & Irwin, N. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.10.025 · Cited by 48
Kasabri, V. N., Al-Hallaq, E. K., Bustanji, Y. K., Abdul‐Razzak, K. K., Abaza, I. F., & Afifi‐Yazar, F. Ü. (2016) · Pharmaceutical Biology · doi:10.1080/13880209.2016.1233567 · Cited by 48
Collino, M., Benetti, E., Rogazzo, M., Mastrocola, R., Yaqoob, M. M., Aragno, M., Thiemermann, C., & Fantozzi, R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.014 · Cited by 51
“Introduction Type 2 diabetes and obesity, recently referred to as “diabesity,” represent two closely linked healthcare challenges of modern societies that continue to rise in prevalence, with devastating health and economic implications [1].”
Peripheral targets in obesity treatment: a comprehensive update
Chatzigeorgiou, A., Kandaraki, E., Papavassiliou, A. G., & Koutsilieris, M. (2014) · Obesity Reviews · doi:10.1111/obr.12163 · Cited by 52
“Another promising combination seems to be the long-acting GLP-GIP coagonists with similarly impressive results on obesity and metabolism in obese rodents (163).”
BackgroundInfluentialA β-Peptide Agonist of the GLP-1 Receptor, a Class B GPCR
Denton, E. V., Craig, C. J., Pongratz, R. L., Appelbaum, J., Doerner, A. E., Narayanan, A., Shulman, G. I., Cline, G. W., & Schepartz, A. (2013) · Organic Letters · doi:10.1021/ol402568j · Cited by 42
Bertocchi, I., Foglietta, F., Collotta, D., Eva, C. E., Brancaleone, V., Thiemermann, C., & Collino, M. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15229 · Cited by 40
“…societies are both associated with an increase in co-morbidities, such as “diabesity,” the association of obesity and diabetes, which defines a combination of primarily metabolic disorders evoked by impairment of both lipids and sugar metabolism (Potenza et al., 2017; Tschop & DiMarchi, 2012).”
BackgroundZambad, S. P., Tuli, D., Matur, A., Ghalsasi, S., Chaudhary, A., Deshpande, S., Gupta, R., Chauthaiwale, V. M., & Dutt, C. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s50209 · Cited by 34
van Witteloostuijn, S. B., Dalbøge, L. S., Hansen, G., Midtgaard, S. R., Jensen, G. V., Jensen, K. J., Vrang, N., Jelsing, J., & Pedersen, S. L. (2017) · Journal of Peptide Science · doi:10.1002/psc.3048 · Cited by 28
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
Self-citationSun, C., Trevaskis, J. L., Jodka, C. M., Neravetla, S., Griffin, P., Xu, K., Wang, Y., Parkes, D. G., Forood, B., & Ghosh, S. S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401418s · Cited by 22
Phytochemical and biological evaluations of Arum hygrophilum boiss. (Araceae)
Afifi, F. U., Kasabri, V. N., Lițescu, S. C., Abaza, I. F., & Tawaha, K. (2017) · Pharmacognosy Magazine · doi:10.4103/0973-1296.204551 · Cited by 14
“[1-3] Type 2 diabetes and obesity, referred to as diabesity, comprise global health threats with rising prevalence.[4] Diverse studies were conducted to explore medicinal plants as potential therapeutic agents for dual management of diabetes and hyperlipidemia via digestive enzymes’ inhibition, namely pancreatic α-amy…”
BackgroundAfifi‐Yazar, F. Ü. (2014) · European Journal of Medicinal Plants · doi:10.9734/ejmp/2014/7022 · Cited by 11
Kumar, V., Thakur, A. K., Verma, S., Yadav, V., & Chatterjee, S. S. (2015) · TANG [HUMANITAS MEDICINE] · doi:10.5667/tang.2014.0026 · Cited by 10
New Perspectives on the Development of Antiobesity Drugs
Costantino, L., & Barlocco, D. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.167 · Cited by 5
Bariatric Surgery and Prevention of Type 2 Diabetes
Zaccardi, F., Pitocco, D., & Ghirlanda, G. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1211380 · Cited by 4
Cardiac natriuretic peptides in plasma: from prediction to precision medicine
Goetze, J. P., & Zois, N. E. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30221-2 · Cited by 3
Müller‐Wieland, D. (2013) · Der Diabetologe · doi:10.1007/s11428-012-1019-6 · Cited by 2
Vázquez, C., Arrieta, F., Piñera, M., Balsa, J. A., Martı́nez-Botas, J., Gómez‐Coronado, D., Calañas, A., Zamarrón, I., & Botella-Carretero, J. I. (2014) · e-SPEN Journal · doi:10.1016/j.clnme.2014.06.004 · Cited by 1
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2014) · Springer eBooks · doi:10.1007/978-3-319-09915-6_21 · Cited by 1
Self-citation
Metadata
- Authors
- Tschöp, M. H., & DiMarchi, R. D.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- Corresponding author
- Tschöp, Matthias H.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-05-14
- Volume
- 61
- Issue
- 6
- Pages
- 1309-1314
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3357302
- OpenAlex
- W2109064292
- Cited by
- 32
- References
- 27
- Citations by year
- 2023: 1 · 2020: 1 · 2019: 1 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 9 · 2012: 2
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabesity, obesity, obesity-related diabetes
- MeSH terms
- Awards and Prizes, Diabetes Mellitus, Type 2, Humans, Obesity, Societies, Scientific, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.